WP
ARTV

Woodline Partners’s Artiva Biotherapeutics ARTV Stock Holding History

Woodline Partners’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-283,124
Closed -$428K – 1075
2025
Q2 		$428K Hold
283,124
– – ﹤0.01% 867
2025
Q1 		$849K Hold
283,124
– – 0.01% 780
2024
Q4 		$2.85M Hold
283,124
– – 0.02% 591
2024
Q3 		$4.37M Buy
+283,124
New +$3.28M 0.04% 403

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners's ARTV Position: Q3 2025 in Review

Woodline Partners sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 283,124 shares — an estimated $428K sold.

Woodline Partners first reported a position in ARTV in Q3 2024 and held it in 4 quarters. The position peaked at $4.37M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Woodline Partners reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 283,124 Artiva Biotherapeutics shares in Q3 2025, an estimated $428K.
  • Woodline Partners first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 4 quarters.
  • Woodline Partners's Artiva Biotherapeutics position peaked at $4.37M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.